0000902664-19-003156.txt : 20190725
0000902664-19-003156.hdr.sgml : 20190725
20190725163322
ACCESSION NUMBER: 0000902664-19-003156
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190723
FILED AS OF DATE: 20190725
DATE AS OF CHANGE: 20190725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avoro Capital Advisors LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 19974826
BUSINESS ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 110 GREENE STREET
STREET 2: SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
FORMER NAME:
FORMER CONFORMED NAME: venBio Select Advisor LLC
DATE OF NAME CHANGE: 20150210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aghazadeh Behzad
CENTRAL INDEX KEY: 0001701815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 19974827
MAIL ADDRESS:
STREET 1: C/O AVORO CAPITAL ADVISORS LLC
STREET 2: 110 GREENE STREET, SUITE 800
CITY: NEW YORK
STATE: NY
ZIP: 10012
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
X0306
4
2019-07-23
1
0001576263
Mirati Therapeutics, Inc.
MRTX
0001633313
Avoro Capital Advisors LLC
110 GREENE STREET
SUITE 800
NEW YORK
NY
10012
0
0
1
0
0001701815
Aghazadeh Behzad
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK
NY
10012
0
0
1
0
Common Stock, $0.001 par value per share
2019-07-23
4
S
0
62500
101.88
D
3800000
I
See footnotes
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.1321 to $104.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
2019-07-25
/s/ Behzad Aghazadeh
2019-07-25